Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is categorized as MCD with high probability by the LymphGen algorithm. This is based on a combination of genetic features and MCD DLBCLs often, but do not always, have the most common hot spot mutation in MYD88 (L265P) and/or activating mutations in CD79B. This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting PIM1 and/or ETV6, which can be coding or non-coding.
Biomarker and diagnostic research for MCD diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for MCD diffuse large B-cell lymphoma.
52 publications have been identified in PubMed for MCD diffuse large B-cell lymphoma. Research spans Diagnostic / Biomarker (23%), Basic Science / Preclinical (21%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 12 | 23% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 9:38 PM UTC
Common questions about MCD diffuse large B-cell lymphoma
Laboratory research
11 |
21% |
Disease patterns and progression | 9 | 17% |
Patient case studies | 7 | 13% |
Clinical study results | 6 | 12% |
Research summaries | 5 | 10% |
Other research | 1 | 2% |
New treatment approaches | 1 | 2% |
Uppal M (2026). [PMID: 42054619](https://pubmed.ncbi.nlm.nih.gov/42054619/). *J Clin Oncol*. [Review / Meta-Analysis]
Tan S (2026). [PMID: 41920769](https://pubmed.ncbi.nlm.nih.gov/41920769/). *Ann Acad Med Singap*. [Other]
Yim J (2026). [PMID: 41544233](https://pubmed.ncbi.nlm.nih.gov/41544233/). *Blood Adv*. [Diagnostic / Biomarker]
Zhu C (2026). [PMID: 41814374](https://pubmed.ncbi.nlm.nih.gov/41814374/). *World J Surg Oncol*. [Case Report / Case Series]
Ohashi KE (2026). [PMID: 41171506](https://pubmed.ncbi.nlm.nih.gov/41171506/). *Int J Hematol*. [Epidemiology / Natural History]
Ito Y (2026). [PMID: 41807658](https://pubmed.ncbi.nlm.nih.gov/41807658/). *Ann Hematol*. [Case Report / Case Series]
Álvarez-Corrales E (2026). [PMID: 41951939](https://pubmed.ncbi.nlm.nih.gov/41951939/). *Leukemia*. [Clinical Trial Publication]
Mularoni A (2026). [PMID: 41615270](https://pubmed.ncbi.nlm.nih.gov/41615270/). *Transpl Infect Dis*. [Review / Meta-Analysis]
Peng F (2026). [PMID: 41410279](https://pubmed.ncbi.nlm.nih.gov/41410279/). *Pathol Int*. [Diagnostic / Biomarker]
Liang JH (2026). [PMID: 41776568](https://pubmed.ncbi.nlm.nih.gov/41776568/). *BMC Med*. [Epidemiology / Natural History]